Back To Search Results


Editor: Manouchkathe Cassagnol Updated: 4/21/2024 9:55:12 PM


Amlodipine is an oral dihydropyridine calcium channel blocker. The FDA initially approved amlodipine besylate in 1987.

FDA-Approved Indications

  • Hypertension: Amlodipine is an excellent first-line choice among the multiple options of antihypertensive agents. It may be used alone or in combination with other antihypertensive agents.[1][2]
  • Chronic stable angina: Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents.[3]  
  • Vasospastic angina (Prinzmetal or variant angina): Amlodipine is indicated to treat confirmed or suspected vasospastic angina.[4] 
  • Angiographically documented coronary artery disease (CAD): In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, amlodipine is indicated to reduce the risk of hospitalization from angina and reduce the risk of a coronary revascularization procedure.[5]

Off-Label Uses

  • Diabetic nephropathy [6]
  • Left ventricular hypertrophy [7]
  • Raynaud phenomenon [8]
  • Silent myocardial ischemia [9][10]
  • Group 1 pulmonary arterial hypertension (PAH): Use only in patients with idiopathic PAH and positive vasodilator testing.[11]
  • Microvascular angina: According to the 2023 AHA/ACC guideline for chronic coronary disease, amlodipine should be considered as a third-line therapy for microvascular angina (non-obstructive coronary artery disease and proven coronary microvascular dysfunction) in patients already on β-blockers.[12] 
  • Kidney transplant recipients: According to the Kidney Disease: Improving Global Outcomes (KDIGO) Management of Blood Pressure in Chronic Kidney Disease guidelines, a dihydropyridine calcium channel blocker such as amlodipine or an angiotensin receptor blocker is recommended as the first-line antihypertensive agent in adult kidney transplant recipients.[13]

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Normally, vascular smooth muscle contraction begins when calcium enters the cell via voltage-dependent L-type calcium channels. The calcium binds to intracellular calmodulin, which binds to and activates myosin light-chain kinase (MLCK). MLCK is responsible for the phosphorylation of the myosin light chain, ultimately leading to muscle contraction and vasoconstriction. Calcium-induced calcium release from the sarcoplasmic reticulum further amplifies the vascular smooth muscle contraction. This sequence of events leads to a decreased vascular cross-sectional area, increased vascular resistance, and increased blood pressure.

Amlodipine blocks the voltage-dependent L-type calcium channels, inhibiting the initial calcium influx. Reduced intracellular calcium causes decreased vascular smooth muscle contractility, increased smooth muscle relaxation, and resultant vasodilation. Additionally, amlodipine is associated with improved vascular endothelial function in patients with hypertension. Amlodipine reduces blood pressure by inducing smooth muscle relaxation and vasodilatation.[3]

Amlodipine's role in relieving stable angina involves the reduction of afterload secondary to its vasodilatory and antihypertensive properties. Reducing afterload lowers myocardial oxygen demand at any level of exertion, as the heart does not need to work as hard to pump blood into the systemic circulation. Amlodipine also alleviates Prinzmetal or variant angina by blocking coronary spasms and restoring blood flow in the coronary arteries.[14]

Raynaud phenomenon (RP) is an excessive vascular response to cold temperature that manifests clinically by color changes of the distal skin of the digits and toes, nose, and earlobes. Amlodipine induces smooth muscle relaxation and is an effective short-term treatment for patients with Raynaud phenomenon.[15]

ACE inhibitors (ACE-Is)/angiotensin receptor blockers (ARBs) are the initial treatment of choice for diabetic nephropathy. However, clinical trials have shown that combined antihypertensive therapy with either amlodipine plus an ARBs/ACE-Is exerts a greater antiproteinuric effect in patients with type 2 diabetic nephropathy.[16][17]

ASCOT (Anglo-Scandinavian Outcome Trial) demonstrated that an amlodipine-based blood pressure regimen decreased the long-term incidence of stroke compared with atenolol, but further research is still required.[18]


Absorption: The absolute bioavailability of amlodipine is between 64% and 90%. Food does not alter the bioavailability of amlodipine. Peak plasma concentrations are achieved between 6 and 12 hours. Steady-state plasma levels are achieved after 7 to 8 days of daily dosing of amlodipine. Patients with hepatic dysfunction have decreased clearance of amlodipine. Accordingly, there is an increase in AUC of approximately 40% to 60% in patients with liver conditions.

Distribution: Amlodipine has high plasma protein binding (93%).

Metabolism: Amlodipine is extensively metabolized by the liver to inactive metabolites. CYP3A4 and CYP3A5 play an important role in the metabolism of amlodipine.[19][20][21]

Excretion: Amlodipine's plasma half-life is biphasic, with a terminal elimination half-life of about 30 to 50 hours, which is increased with hepatic dysfunction. Amlodipine is primarily excreted renally; 10% of the parent compound and 60% of the metabolites are excreted in the urine.


Available Dosage Forms and Strengths

Amlodipine is primarily administered orally and is available in 2.5, 5, and 10 mg tablets. Additionally, suspensions created from oral tablets are available for pediatric and older patients with difficulty swallowing. Compared to nifedipine and other medications in the dihydropyridine class, amlodipine has the longest half-life at 30 to 50 hours. The benefit of such a long half-life is having once-daily dosing.[22]

Recommended Dosages


  • Adults: Initial dose of 5 mg; maximum dose of 10 mg daily
  • Older and debilitated patients: Reduce initial dose to 2.5 mg; maximum dose of 10 mg daily
  • Adolescents and children aged 6 years or older: 2.5 to 5 mg once daily; maximum dose of 5 mg daily
  • Children aged 6 years old or younger: 0.05 to 0.2 mg/kg/d; maximum dose 0.3 to 0.6 mg/kg/d (up to 5 mg/d) [23]

CAD, Chronic Stable Angina, Prinzmental Angina, CAD Documented by Angiography and Without Heart Failure or Ejection Fraction Less than 40%

  • Adults: Initial dose 5 to 10 mg once daily
  • Older and debilitated patients: The initial dose is 5 mg once daily; the maintenance dose is 10 mg once daily.[4]

Amlodipine can be used as monotherapy or in combination with several different medications to manage hypertension or CAD. Common combinations include:

  • Amlodipine/atorvastatin: Atorvastatin is a lipid-lowering agent that blocks cholesterol synthesis and is administered to reduce cardiovascular events.[24][25]
  • Amlodipine/aliskiren or amlodipine/aliskiren/hydrochlorothiazide: Aliskiren is a direct renin inhibitor that binds renin and prevents activating the renin-angiotensin-aldosterone system (RAAS). Hydrochlorothiazide is a thiazide diuretic that leads to a reduction in blood volume. Both combinations lower blood pressure.[26][27]
  • Amlodipine/benazepril or amlodipine/perindopril: Benazepril and perindopril are ACE inhibitors that block the conversion of angiotensin I to angiotensin II in the RAAS.[28]
  • Amlodipine/olmesartan or amlodipine/telmisartan or amlodipine/valsartan: Olmesartan, telmisartan, and valsartan are angiotensin II receptor blockers (ARBs) that inhibit the activity of angiotensin II in the RAAS.[29][30]
  • Amlodipine/valsartan/hydrochlorothiazide: A randomized controlled trial demonstrated the efficacy of triple therapy (amlodipine/valsartan/hydrochlorothiazide) for moderate or severe hypertension.[31][32]

Specific Patient Population

Hepatic impairment: Amlodipine is primarily metabolized by the liver, and the plasma elimination half-life is prolonged with impaired hepatic function; gradual titration of the dose is recommended. The initial dose is 2.5 mg once daily for hypertension or 5 mg once daily for angina. Adjust the dosage based on clinical response.[2]

Renal impairment: Renal impairment does not significantly influence the pharmacokinetics of amlodipine. Consequently, patients with renal impairment do not require dose adjustment.

Pregnancy considerations: Untreated hypertension in pregnancy increases the risk of preeclampsia, premature delivery, intrauterine growth restriction (IUGR), and intrauterine death. Chronic Hypertension and Pregnancy (CHAP) results indicate that in pregnant women with mild chronic hypertension, an approach of target blood pressure of less than 140/90 mm Hg was associated with better pregnancy outcomes than a strategy of reserving treatment only for severe hypertension.[33] Based on these findings, the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) guidelines suggest treatment with antihypertensive agents for mild chronic hypertension in pregnancy to a goal BP of <140/90 mm Hg.[34] Calcium channel blockers are widely used in pregnancy, and ACOG suggests other agents such as labetalol, nifedipine, and methyldopa.[35] However, amlodipine exposure in pregnancy does not appear to be associated with increased fetal malformations compared with other antihypertensive medications or maternal hypertension without treatment.[36] Based on a recent meta-analysis, amlodipine can also be used safely for hypertension during pregnancy.[37]

Breastfeeding considerations: Human milk levels of amlodipine are low, and plasma levels in breastfed infants are undetectable. Maternal use of amlodipine during breastfeeding has not caused any adverse effects in breastfed infants. Amlodipine is acceptable in nursing mothers.[36][38]

Pediatric patients: The efficacy and safety of amlodipine in children younger than 6 years old remain uncertain. Per the guidelines from the American Heart Association and American Thoracic Society for pediatric pulmonary hypertension, amlodipine doses should always be titrated up from a lower dose. A trial of amlodipine should be performed only in those patients who have positive acute vasoreactivity testing with nitric oxide or epoprostenol. In children with a previous history of high-altitude pulmonary edema (HAPE), amlodipine may be deemed a reasonable option for prophylaxis.[39]

Older patients: When prescribing amlodipine for older individuals, it's advisable to exercise caution, typically initiating treatment at the lower end of the dosage spectrum. This approach acknowledges the higher likelihood of impaired hepatic or cardiac function, as well as the increased incidence of accompanying diseases or concurrent medication usage. Older patients may have decreased clearance, leading to increased AUC, necessitating a lower initial dose.[2]

Adverse Effects

The significant adverse effects of amlodipine include peripheral edema, heart failure, pulmonary edema, flushing, dizziness, headache, drowsiness, skin rash, nausea, abdominal pain, and constipation. Researchers observed edema, dizziness, flushing, and palpitations in controlled clinical trials in a dose-dependent manner. For example, at a dose of 10 mg, the incidence of edema, dizziness, flushing, and palpitations was 10.8%, 3.4%, 2.6%, and 4.5%, respectively. The incidence of headaches, fatigue, nausea, and abdominal pain was 7.3%, 4.5%, 2.9%, and 1.6%, respectively.[40] 

Calcium channel blockers, including amlodipine, have been linked to rare instances of idiosyncratic drug-induced liver disease. A mixed hepatocellular-cholestatic pattern is typical of amlodipine-induced liver injury.[41] Patients have complete recovery 4 to 8 weeks after stopping the drug.[42] Amlodipine-induced gingival hyperplasia is a common adverse effect. Maintaining good oral hygiene practices is beneficial for prevention. In cases where gingival hyperplasia persists despite these measures, surgical intervention may be necessary.[43]

Drug-Drug Interactions

Coadministration of amlodipine and clarithromycin or erythromycin has reportedly increased the risk of hypotension and acute kidney injury due to decreased metabolism by CYP3A4.[44] Additionally, when amlodipine is used with high doses of statins, there is an increased risk for myopathy and rhabdomyolysis.[45] The interaction with tacrolimus is described in the monitoring section.

Prescribing Cascade

It is important to note that amlodipine can cause peripheral edema. A prescribing cascade occurs when the edema is mistaken as a new medical condition, and a diuretic is consequently prescribed to treat the edema.[46]


Amlodipine is contraindicated in patients with known hypersensitivity to amlodipine or its dosage form components. Lymphocyte transformation test (LTT) can be used to diagnose drug allergy.[47]

Warning and Precautions

Amlodipine is contraindicated in patients with cardiogenic shock, severe aortic stenosis, unstable angina, severe hypotension, heart failure, and hepatic impairment. According to the manufacturer's labeling, patients with severe coronary artery disease may have worsening angina after initiating amlodipine therapy. In cardiogenic shock, the heart cannot pump effectively, exacerbated by inhibiting the influx of calcium ions into cardiac cells. In severe aortic stenosis, amlodipine can cause ventricular collapse and dysfunction. Amlodipine causes a reflexive increase in cardiac contractility in unstable angina, increasing myocardial oxygen demand and worsening ischemia. Amlodipine can further reduce blood pressure, causing hypoperfusion to vital organs and syncope in patients with severe hypotension.[48] Patients with heart failure may experience pulmonary edema, shortness of breath, and dyspnea with amlodipine.[49] Patients with hepatic impairment may not metabolize amlodipine effectively, leading to a longer half-life with possible increases in plasma concentrations.[50]


In general, laboratory monitoring is not necessary for patients taking amlodipine. Since amlodipine is an antihypertensive medication, clinicians and patients should regularly measure blood pressure to achieve target levels per the 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines. Furthermore, the healthcare team should monitor patients for adverse effects such as peripheral edema, dizziness, and flushing.[51]

Amlodipine may increase the AUC of tacrolimus. In one study, amlodipine decreased the tacrolimus clearance by 2.2 to 3.8 fold, increasing AUC and systemic exposure in CYP3A5 expressers. Monitoring of trough blood levels of tacrolimus is recommended.[52]


Signs and Symptoms of Overdose

Amlodipine overdose and toxicity can lead to massive vasodilation, hypotension, and reflex tachycardia as compensatory mechanisms. Prolonged systemic hypotension can progress to shock and even death.

Management of Overdose

Activated charcoal (AC) should be administered to patients with amlodipine overdose. The hypotension usually remits intravenous (IV) fluid resuscitation, IV calcium gluconate, and vasopressor therapy with norepinephrine or dopamine. High-dose insulin is also sometimes administered as research has shown it lowers mortality and improves hemodynamics. Electrocardiographic results, vital signs, kidney function, urine output, and electrolytes require continual monitoring during an overdose.[48][53] As amlodipine has high plasma protein binding, hemodialysis is not likely to be beneficial. A recent case report describes successful resin hemadsorption/hemoperfusion treatment for amlodipine overdose, demonstrating its efficacy in resolving severe toxicity and hemodynamic instability.[54]

Enhancing Healthcare Team Outcomes

Amlodipine is a first-line choice among the myriad options of antihypertensive agents. Amlodipine has also shown robust reductions in cardiovascular endpoints (especially stroke). In addition, compared to nifedipine and other medications in the dihydropyridine class, amlodipine has the longest half-life at 30 to 50 hours. The benefit of such a long half-life is having once-daily dosing. Therefore, healthcare providers, including physicians, nurse practitioners, physician assistants, and pharmacists, should be familiar with the indications and contraindications of amlodipine. However, the drug can cause severe hypotension in overdose; it is recommended to titrate the dose with an initial low dose gradually. In addition, long-term patient monitoring is necessary for optimal blood pressure control. The PERSONAL-CovidBP trial demonstrated that smartphone-enabled remote precision dosing of amlodipine effectively lowered blood pressure in individuals with primary hypertension during the COVID-19 pandemic.[55]

Amlodipine therapy requires the participation of the entire interprofessional healthcare team. Clinicians (MDs, DOs, NPs, PAs) and specialists will typically initiate treatment. The pharmacist should report to the clinician for potential drug interactions (eg, simvastatin or erythromycin). In addition, pharmacists should verify dosing and educate the patient about the common adverse drug reactions. The nurse should assess patient adherence and offer to counsel on medication administration. Both nursing and pharmacy staff should alert the prescriber if they encounter any issues. In an acute overdose of amlodipine, emergency physicians and triage nurses should stabilize the patient with a primary focus on circulation. In a massive overdose of amlodipine, it is important to obtain an emergency consultation with a medical toxicologist. Critical care physician supervision is necessary for patients requiring vasopressor therapy in MICU.

The interprofessional team approach can improve patient outcomes related to amlodipine therapy by maximizing efficacy and minimizing the risk of adverse drug reactions. In addition, a pragmatic randomized controlled trial indicated that team-based care (TBC) involving community pharmacists and nurses working in an interprofessional manner with clinicians could accomplish long-term blood pressure control related to antihypertensive therapy, including calcium channel blockers.[56]



McCormack T, Krause T, O'Flynn N. Management of hypertension in adults in primary care: NICE guideline. The British journal of general practice : the journal of the Royal College of General Practitioners. 2012 Mar:62(596):163-4. doi: 10.3399/bjgp12X630232. Epub     [PubMed PMID: 22429432]


Fares H, DiNicolantonio JJ, O'Keefe JH, Lavie CJ. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open heart. 2016:3(2):e000473     [PubMed PMID: 27752334]


Ferrari R, Pavasini R, Camici PG, Crea F, Danchin N, Pinto F, Manolis A, Marzilli M, Rosano GMC, Lopez-Sendon J, Fox K. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. European heart journal. 2019 Jan 7:40(2):190-194. doi: 10.1093/eurheartj/ehy504. Epub     [PubMed PMID: 30165445]

Level 1 (high-level) evidence


Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV, Anderson JL, American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012 Dec 18:126(25):e354-471. doi: 10.1161/CIR.0b013e318277d6a0. Epub 2012 Nov 19     [PubMed PMID: 23166211]

Level 1 (high-level) evidence


Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000 Sep 26:102(13):1503-10     [PubMed PMID: 11004140]

Level 1 (high-level) evidence


Tabur S, Oğuz E, Sabuncu T, Korkmaz H, Çelik H. The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. Clinical and experimental hypertension (New York, N.Y. : 1993). 2015:37(3):177-83. doi: 10.3109/10641963.2014.933964. Epub 2014 Jul 22     [PubMed PMID: 25050869]

Level 1 (high-level) evidence


Ostroumova OD, Kochetkov AI. [Effects of Amlodipine/Lisinopril Fixed-Dose Combination on Severity of Left Ventricular Hypertrophy and Parameters of Myocardial Stiffness in Patients With Hypertension]. Kardiologiia. 2016 Dec:56(11):27-37     [PubMed PMID: 28290816]


Lee EY, Park JK, Lee W, Kim YK, Park CS, Giles JT, Park JW, Shin K, Lee JS, Song YW, Lee EB. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study. Rheumatology (Oxford, England). 2014 Apr:53(4):658-64. doi: 10.1093/rheumatology/ket417. Epub 2013 Dec 17     [PubMed PMID: 24352340]

Level 1 (high-level) evidence


Perna GP, Valle G, Cianfrone N, Luca GD, Amico C, Coli C. Amlodipine in ischaemic left ventricular dysfunction with mild to moderate heart failure. Clinical drug investigation. 1998:16(4):289-96     [PubMed PMID: 18370550]


Leonard L, Phillips WJ. Near-complete migraine prophylaxis with amlodipine: a case report. Journal of pain and symptom management. 2007 Dec:34(6):571-3     [PubMed PMID: 18053876]

Level 3 (low-level) evidence


Velayati A, Valerio MG, Shen M, Tariq S, Lanier GM, Aronow WS. Update on pulmonary arterial hypertension pharmacotherapy. Postgraduate medicine. 2016 Jun:128(5):460-73. doi: 10.1080/00325481.2016.1188664. Epub     [PubMed PMID: 27232660]


Writing Committee Members, Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2023 Aug 29:82(9):833-955. doi: 10.1016/j.jacc.2023.04.003. Epub 2023 Jul 20     [PubMed PMID: 37480922]

Level 1 (high-level) evidence


Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney international. 2021 Mar:99(3S):S1-S87. doi: 10.1016/j.kint.2020.11.003. Epub     [PubMed PMID: 33637192]

Level 1 (high-level) evidence


Tang L, Gamal El-Din TM, Swanson TM, Pryde DC, Scheuer T, Zheng N, Catterall WA. Structural basis for inhibition of a voltage-gated Ca(2+) channel by Ca(2+) antagonist drugs. Nature. 2016 Sep 1:537(7618):117-121. doi: 10.1038/nature19102. Epub 2016 Aug 24     [PubMed PMID: 27556947]


Pope J. Raynaud's phenomenon (primary). BMJ clinical evidence. 2013 Oct 10:2013():1119     [PubMed PMID: 24112969]

Level 1 (high-level) evidence


Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England journal of medicine. 2001 Sep 20:345(12):851-60     [PubMed PMID: 11565517]

Level 1 (high-level) evidence


Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertension research : official journal of the Japanese Society of Hypertension. 2002 Nov:25(6):849-55     [PubMed PMID: 12484508]

Level 3 (low-level) evidence


Whiteley WN, Gupta AK, Godec T, Rostamian S, Whitehouse A, Mackay J, Sever PS. Long-Term Incidence of Stroke and Dementia in ASCOT. Stroke. 2021 Oct:52(10):3088-3096. doi: 10.1161/STROKEAHA.120.033489. Epub 2021 Jul 1     [PubMed PMID: 34192893]


Zhu Y, Wang F, Li Q, Zhu M, Du A, Tang W, Chen W. Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug metabolism and disposition: the biological fate of chemicals. 2014 Feb:42(2):245-9. doi: 10.1124/dmd.113.055400. Epub 2013 Dec 3     [PubMed PMID: 24301608]


Cataldi M, Celentano C, Bencivenga L, Arcopinto M, Resnati C, Manes A, Dodani L, Comnes L, Vander Stichele R, Kalra D, Rengo G, Giallauria F, Trama U, Ferrara N, Cittadini A, Taglialatela M. Identification of Drugs Acting as Perpetrators in Common Drug Interactions in a Cohort of Geriatric Patients from Southern Italy and Analysis of the Gene Polymorphisms That Affect Their Interacting Potential. Geriatrics (Basel, Switzerland). 2023 Aug 24:8(5):. doi: 10.3390/geriatrics8050084. Epub 2023 Aug 24     [PubMed PMID: 37736884]


Liang H, Zhang X, Ma Z, Sun Y, Shu C, Zhu Y, Zhang Y, Hu S, Fu X, Liu L. Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension. Pharmacogenomics and personalized medicine. 2021:14():189-197. doi: 10.2147/PGPM.S291277. Epub 2021 Feb 2     [PubMed PMID: 33564260]


van Zwieten PA. Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. Clinical cardiology. 1994 Sep:17(9 Suppl 3):III3-6     [PubMed PMID: 9156957]

Level 3 (low-level) evidence


Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2020 Jun:75(6):1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026. Epub 2020 May 6     [PubMed PMID: 32370572]

Level 1 (high-level) evidence


Athyros VG, Katsiki N, Karagiannis A. Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients. Current medical research and opinion. 2013 Jul:29(7):791-2. doi: 10.1185/03007995.2013.805536. Epub 2013 May 29     [PubMed PMID: 23672630]

Level 3 (low-level) evidence


Curran MP. Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. Drugs. 2010:70(2):191-213. doi: 10.2165/11204420-000000000-00000. Epub     [PubMed PMID: 20108992]


Teo KK, Pfeffer M, Mancia G, O'Donnell M, Dagenais G, Diaz R, Dans A, Liu L, Bosch J, Joseph P, Copland I, Jung H, Pogue J, Yusuf S, Aliskiren Prevention of Later Life Outcomes trial Investigators. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. European heart journal. 2014 Jul:35(26):1743-51. doi: 10.1093/eurheartj/ehu079. Epub 2014 Mar 9     [PubMed PMID: 24616335]

Level 1 (high-level) evidence


Zion AS, Izzo JL Jr. Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results. Expert review of cardiovascular therapy. 2011 Apr:9(4):421-7. doi: 10.1586/erc.11.23. Epub 2011 Mar 18     [PubMed PMID: 21417713]


Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. Journal of the American Heart Association. 2018 Jan 4:7(1):. doi: 10.1161/JAHA.117.006940. Epub 2018 Jan 4     [PubMed PMID: 29301757]


Ruilope LM, SEVITENSION Study Investigators. Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes. Journal of clinical hypertension (Greenwich, Conn.). 2016 Jun:18(6):528-35. doi: 10.1111/jch.12673. Epub 2015 Sep 23     [PubMed PMID: 26395174]


Wang KL, Yu WC, Lu TM, Chen LC, Leu HB, Chiang CE. Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial. Journal of the Chinese Medical Association : JCMA. 2020 Oct:83(10):900-905. doi: 10.1097/JCMA.0000000000000386. Epub     [PubMed PMID: 33009241]

Level 1 (high-level) evidence


Zhang ZY, Yu YL, Asayama K, Hansen TW, Maestre GE, Staessen JA. Starting Antihypertensive Drug Treatment With Combination Therapy: Controversies in Hypertension - Con Side of the Argument. Hypertension (Dallas, Tex. : 1979). 2021 Mar 3:77(3):788-798. doi: 10.1161/HYPERTENSIONAHA.120.12858. Epub 2021 Feb 10     [PubMed PMID: 33566687]


Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension (Dallas, Tex. : 1979). 2009 Jul:54(1):32-9. doi: 10.1161/HYPERTENSIONAHA.109.131300. Epub 2009 May 26     [PubMed PMID: 19470877]

Level 1 (high-level) evidence


Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson K, Haas DM, Plante L, Metz T, Casey B, Esplin S, Longo S, Hoffman M, Saade GR, Hoppe KK, Foroutan J, Tuuli M, Owens MY, Simhan HN, Frey H, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Kinzler W, Su E, Krishna I, Nguyen N, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Galis ZS, Harper L, Ambalavanan N, Geller NL, Oparil S, Cutter GR, Andrews WW, Chronic Hypertension and Pregnancy (CHAP) Trial Consortium. Treatment for Mild Chronic Hypertension during Pregnancy. The New England journal of medicine. 2022 May 12:386(19):1781-1792. doi: 10.1056/NEJMoa2201295. Epub 2022 Apr 2     [PubMed PMID: 35363951]

Level 3 (low-level) evidence


Society for Maternal-Fetal Medicine; Publications Committee. Electronic address: Society for Maternal-Fetal Medicine Statement: Antihypertensive therapy for mild chronic hypertension in pregnancy-The Chronic Hypertension and Pregnancy trial. American journal of obstetrics and gynecology. 2022 Aug:227(2):B24-B27. doi: 10.1016/j.ajog.2022.04.011. Epub 2022 Apr 19     [PubMed PMID: 35710594]


American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstetrics and gynecology. 2019 Jan:133(1):e26-e50. doi: 10.1097/AOG.0000000000003020. Epub     [PubMed PMID: 30575676]


Malha L, August P. Safety of Antihypertensive Medications in Pregnancy: Living With Uncertainty. Journal of the American Heart Association. 2019 Aug 6:8(15):e013495. doi: 10.1161/JAHA.119.013495. Epub 2019 Jul 26     [PubMed PMID: 31345085]


Yin J, Mei Z, Shi S, Du P, Qin S. Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis. Archives of gynecology and obstetrics. 2022 Dec:306(6):1891-1900. doi: 10.1007/s00404-022-06504-5. Epub 2022 Mar 19     [PubMed PMID: 35305140]

Level 1 (high-level) evidence


. Amlodipine. Drugs and Lactation Database (LactMed®). 2006:():     [PubMed PMID: 29999724]


Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Thébaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL, American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015 Nov 24:132(21):2037-99. doi: 10.1161/CIR.0000000000000329. Epub 2015 Nov 3     [PubMed PMID: 26534956]


Vukadinović D, Scholz SS, Messerli FH, Weber MA, Williams B, Böhm M, Mahfoud F. Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. Journal of hypertension. 2019 Oct:37(10):2093-2103. doi: 10.1097/HJH.0000000000002145. Epub     [PubMed PMID: 31107359]

Level 1 (high-level) evidence


. Calcium Channel Blockers. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():     [PubMed PMID: 31643892]


. Amlodipine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():     [PubMed PMID: 31643900]


Okumuş ÖF. Treatment of Gingival Growth Due to Amlodipine Use With a 445-nm Diode Laser: A Case Report. Cureus. 2022 Dec:14(12):e32592. doi: 10.7759/cureus.32592. Epub 2022 Dec 16     [PubMed PMID: 36660514]

Level 3 (low-level) evidence


Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013 Dec 18:310(23):2544-53. doi: 10.1001/jama.2013.282426. Epub     [PubMed PMID: 24346990]

Level 2 (mid-level) evidence


Siriangkhawut M, Tansakul P, Uchaipichat V. Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. 2017 Sep:25(6):823-829. doi: 10.1016/j.jsps.2016.12.006. Epub 2016 Dec 23     [PubMed PMID: 28951665]


Savage RD, Visentin JD, Bronskill SE, Wang X, Gruneir A, Giannakeas V, Guan J, Lam K, Luke MJ, Read SH, Stall NM, Wu W, Zhu L, Rochon PA, McCarthy LM. Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension. JAMA internal medicine. 2020 May 1:180(5):643-651. doi: 10.1001/jamainternmed.2019.7087. Epub     [PubMed PMID: 32091538]


Monge-Ortega OP, Domínguez-Ortega J, González-Muñoz M, Cabañas R, Lluch-Bernal M, Fiandor A, Bravo-Gallego LY, Quirce S. [Delayed allergic reaction to amlodipine with a positive lymphocyte transformation test]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993). 2017 Oct-Dec:64(4):505-508     [PubMed PMID: 29249113]


Agarwal MA, Flatt D, Khouzam RN. The potential detrimental effects of calcium channel blockers' overdose and current available management. Annals of translational medicine. 2018 Jan:6(1):16. doi: 10.21037/atm.2018.01.03. Epub     [PubMed PMID: 29404362]


de Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. American heart journal. 2000 Feb:139(2 Pt 1):185-94     [PubMed PMID: 10650289]


Abernethy DR, Schwartz JB. Pharmacokinetics of calcium antagonists under development. Clinical pharmacokinetics. 1988 Jul:15(1):1-14     [PubMed PMID: 3042243]


. . :():     [PubMed PMID: 26102977]


Zuo XC, Zhou YN, Zhang BK, Yang GP, Cheng ZN, Yuan H, Ouyang DS, Liu SK, Barrett JS, Li PJ, Liu Z, Tan HY, Guo R, Zhou LY, Xie YL, Li ZJ, Li J, Wang CJ, Wang JL. Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. Drug metabolism and pharmacokinetics. 2013:28(5):398-405     [PubMed PMID: 23438946]

Level 1 (high-level) evidence


St-Onge M, Dubé PA, Gosselin S, Guimont C, Godwin J, Archambault PM, Chauny JM, Frenette AJ, Darveau M, Le Sage N, Poitras J, Provencher J, Juurlink DN, Blais R. Treatment for calcium channel blocker poisoning: a systematic review. Clinical toxicology (Philadelphia, Pa.). 2014 Nov:52(9):926-44. doi: 10.3109/15563650.2014.965827. Epub 2014 Oct 6     [PubMed PMID: 25283255]

Level 3 (low-level) evidence


Omar S, Parris P, Gurke CR. Hemoadsorption Therapy for Calcium Channel Blocker Overdose: A Case Report. The Journal of emergency medicine. 2024 Apr:66(4):e463-e466. doi: 10.1016/j.jemermed.2023.11.022. Epub 2023 Dec 9     [PubMed PMID: 38461133]

Level 3 (low-level) evidence


Collier DJ, Taylor M, Godec T, Shiel J, James R, Chowdury Y, Ebano P, Monk V, Patel M, Pheby J, Pheby R, Foubister A, David C, Saxena M, Richardson L, Siddle J, Timlin G, Goldsmith P, Deeming N, Poulter NR, Gabe R, McManus RJ, Caulfield MJ. Personalized Antihypertensive Treatment Optimization With Smartphone-Enabled Remote Precision Dosing of Amlodipine During the COVID-19 Pandemic (PERSONAL-CovidBP Trial). Journal of the American Heart Association. 2024 Feb 20:13(4):e030749. doi: 10.1161/JAHA.123.030749. Epub 2024 Feb 7     [PubMed PMID: 38323513]


Santschi V, Wuerzner G, Pais B, Chiolero A, Schaller P, Cloutier L, Paradis G, Burnier M. Team-Based Care for Improving Hypertension Management: A Pragmatic Randomized Controlled Trial. Frontiers in cardiovascular medicine. 2021:8():760662. doi: 10.3389/fcvm.2021.760662. Epub 2021 Oct 25     [PubMed PMID: 34760950]

Level 1 (high-level) evidence